Top Markets
#1 DogBull DogBull +106.37%
#2 ADO Protocol ADO Protocol +51.14%
#3 Siacoin Siacoin +50.69%
#4 The Bitcoin Bull The Bitcoin Bull +44.16%
#5 MarsCoin MarsCoin +36.63%
#6 龙虾 (Lobster) 龙虾 (Lobster) +30.76%
#7 Glidr Glidr +27.02%
#8 Ontology Gas Ontology Gas +23.03%
#9 UnifAI Network UnifAI Network +19.91%
#10 Falcon Finance Falcon Finance +17.55%
Coin of the day
DogBull DogBull
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Rankning i aktier #15657
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Aktiekurs
$0.63963115
Senast synkroniserad: 2026-08-26
Marknadsvärde
$339.16M
Förändring (1 dag)
0.00%
Förändring (1 år)
-35.23%
Land
CN
Handel Jiangsu Recbio Technology Co., Ltd. (2179)

Kategori

Healthcare
Aktiekurshistorik för Jiangsu Recbio Technology Co., Ltd. (2179)
Högsta slutkurs: $0.64 den 2026-08-01

Lägsta slutkurs: $3.22 den 2022-03-01
Aktiekurshistorik för Jiangsu Recbio Technology Co., Ltd. från 2022 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) 4.07%
2025 -37.60%
2024 -16.16%
2023 -55.93%
2022 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $550.06 40.67%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.03%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $150.50 524.74%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.37 -11.93%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $748.60 4.92%
CH